Retail investors who applied for the Gujarat Kidney and Super Speciality IPO are waiting for the final allotment, which is set to be confirmed on December 26.
Allotment Details
How to check your status
You can view your allotment through two easy methods once the list is finalised:
- Registrar portal (MUFG Intime India): Go to https://www.mufgintime.com/ipo/, select “Gujarat Kidney” from the dropdown, enter your PAN or application number, and click Submit.
- BSE website: Visit https://www.bseindia.com/investors/appli_check.aspx, choose “Equity”, pick “Gujarat Kidney”, and enter your application details or PAN.
If you do not receive an allotment, refunds are expected on December 29, with any credited amount appearing in your bank account the same day. The shares will be credited to demat accounts on the listing day, December 30, when the stock starts trading on both BSE and NSE.
Subscription Summary
The public issue raised Rs 251 crore and was subscribed 5.21 times overall. Retail investors showed the strongest interest, subscribing their portion 19.04 times. Non‑institutional investors subscribed 5.73 times, while qualified institutional buyers (QIBs) subscribed only 1.06 times. Anchor investors had already taken up about 40% of the issue before the IPO opened.
Market Sentiment
In the grey market, the Gujarat Kidney IPO is trading at a 0% premium, suggesting that traders expect the listing price to be close to the issue price of Rs 114 per share. A flat premium typically means there isn’t an anticipated big jump on the first trading day.
Company Overview
Gujarat Kidney and Super Speciality runs a network of multispecialty hospitals focused on secondary and tertiary care, primarily in central Gujarat. Since its incorporation in 2019, the group operates seven hospitals and four pharmacies, with a total of 340 beds as of June 2025.
- Core strengths: Renal and urology services, plus orthopaedics, cardiology, obstetrics, and minimally invasive procedures.
- Financial growth: Revenue surged to Rs 40.4 crore in FY25 from Rs 5.48 crore in FY24. PAT rose to Rs 9.5 crore from Rs 1.71 crore, and EBITDA margins expanded to over 41%.
Use of IPO Proceeds
The funds will mainly support expansion and acquisitions, including:
- Purchase of Parekhs Hospital in Ahmedabad
- Construction of a new hospital in Vadodara
- Partial payment for an already‑acquired medical centre
- Acquisition of robotic surgery equipment
- Repayment of certain borrowings
- Increasing stake in a subsidiary hospital in Bharuch
Valuation Note
At the issue price, the stock is valued at roughly 41.6 times its post‑IPO earnings, which many analysts consider high for a regional hospital chain operating in a competitive market.
Disclaimer
Remember, this is just an overview, not a prediction. Do your own research and consider your risk tolerance before making any investment decisions.